Inducible control of gene expression: Prospects for gene therapy

Current Opinion in Chemical Biology

Volumn 2, Issue 4, 1998, Pages 512-518

  Harvey, Diane M ^a   Caskey, C Thomas ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; ECDYSONE; HORMONE ANTAGONIST; MIFEPRISTONE; PROGESTERONE; RAPAMYCIN; TETRACYCLINE;

ANIMAL; DIMERIZATION; DRUG ANTAGONISM; GENE THERAPY; GENETICS; HUMAN; REVIEW; TRANSACTIVATION;

ANIMALS; DIMERIZATION; ECDYSONE; GENE THERAPY; HORMONE ANTAGONISTS; HUMANS; MIFEPRISTONE; PROGESTERONE; SIROLIMUS; TETRACYCLINE; TRANS-ACTIVATION (GENETICS);

EID: 0032134253     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1367-5931(98)80128-2     Document Type: Article

References (47)

1. Yarranton GT: Inducible vectors for expression in mammalian cells. Curr Opin Biotechnol 1992, 3:506-511.
2. Miller N, Whelan NJ: Progress in transcriptional targeted and regulatable vectors for genetic therapy. Hum Gene Ther 1997, 8:803815.
3. Allgood VE, Eastman EM: Chimeric receptors as gene switches. Curr Opin Biotechnol 1997, 8:474-479.
4. Saez E, No D, West A, Evans RMn: Inducible gene expression in mammalian cells and transgenic mice. Curr Opin Biotechnol 1997, 8:608-616.
5. Clackson T: Controlling mammalian gene expression with small molecules. Curr Opin Chem Biol 1997, 1:210-218.
6. Gossen M, Bujard H: Tight control of gene expression in mammalian cells by tet-responsive promoters. Proc Natl Acad Sci USA 1992, 89:5547-5551.
7. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H: Transcriptional activation by tets in mammalian cells. Science 1995, 268:1766-1769.
8. Jost M, Kari C, Rodeck U: An episomal vector for stable tet-regulated gene expression. Nucleic Acid Res 1997, 25:3131-3134.
9. Paulus W, Baur I, Oberer DM, Breakfield XO, Reeves SA: Regulated expression of diptheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. J Neurosurg 1997, 87:89-95.
10. Hwang JJ, Scuric Z, Anderson WF: Novel retroviral vector transferring a suicide gene and a selectable marker gene with enhanced gene expression by using a tet-responsive expression system. J Virol 1996, 70:8138-8141.
11. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, Lubbert H, Bujard H: Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci USA 1996, 93:10933-10938.
12. Bohl D, Naffakh N, Heard JM: Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 1997, 3:299-305. This paper describes the use of retroviral vectors to transduce primary myoblasts with reverse tetracycline transactivator (rtTA) and inducible erythropoietin (Epo). Following implantation into C3H mice, Epo secretion could be switched on and off in a doxycycline-dependent manner. There was no apparent immune response against rtTA expression recipient animals, as Epo secretion persisted for five months.
13. Lindemann D, Patriquin E, Feng S, Mulligan RC: Versatile retrovirus vector systems for regulated gene expression in vitro and in vivo. Mol Med 1997, 3:466-476. This publication describes the development and evaluation of one- and two-retrovirus based systems for transduction of tetracycline-controlled transactivator or reverse tetracycline transactivator and an inducible gene of interest. Similar to experiments described in [11], doxycycline-dependent induction of human growth hormone secretion could be observed at 16 and 46 days after transplantation into recipient mice.
14. Watsuji T, Okamoto Y, Emi N, Katsuoka Y, Hagiwara M: Controlled gene expression with a reverse tet-regulated retroviral vector (RTRV) system. Biochem Biophys Res Comm 1997, 234:769-773.
15. Klein NC, Cunha BA: Tetracyclines. Med Clin North Am 1995, 79:789-801.
16. Cohlan SQ: Tetracycline staining of teeth. Teratology 1977, 15:127-130.
17. Yao T-P, Segraves WA, Oro AE, McKeown M, Evans RM: Drosophila ultraspiracle modulates ecdysone receptor function via heterodimer formation. Cell 1992, 71:63-72.
18. Yao T-P, Forman BM, Jiang Z, Cherbas L, Chen J-D, McKeown M, Cherbas P, Evans RM: Functional ecdysone receptor is the product of EcR and Ultraspiracle genes. Nature 1993, 366:476-479.
19. Christopherson KS, Mark MR, Bajaj V, Godowski PJ: Ecdysteroid-dependent regulation of genes in mammalian cells by a Drosophila ecdysone and chimeric transactivators. Proc Natl Acad Sci USA 1992, 89:6314-6318.
20. No D, Yao T-P, Evans RM: Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc Natl Acad Sci USA 1996, 93:3346-3351.
21. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992, 355:446-449.
22. Bugge TH, Pohl J, Lonnoy O, Stunnenberg HG: RXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBO J 1992, 11:1409-1418.
23. Pemrick SM, Lucas DA, Grippo JF: The retinoid receptors. Leukemia 1994, 8:1797-1806.
24. Wang Y, O'Malley BW Jr, Tsai SY, O'Malley BW: A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 1994, 91:8180-8184.
25. Delort JP, Cappechi MR: TAXI/UAS: a molecular switch to control expression of genes in vivo. Hum Gene Ther 1996, 7:809-820.
26. Garcia T, Benhamou B, Gofflo D, Vergezac A, Philibart D, Chambon P, Gronemeyer H: Switching agonistic, antagonistic, and mixed transcriptional responses to 11 b-substituted progestins by mutation of the progesterone receptor. Mol Endocrinol 1992, 6:2071-2078.
27. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992, 69:703-713.
28. Wang Y, DeMayo FJ, Tsai SY, O'Malley BW: Ligand-inducible and liver-specific target gene expression in transgenic mice. Nat Biotechnol 1997, 15:239-243. The RU486-inducible system described in [21] is evaluated in double transgenic mice expressing the GLVP transactivator (a transactivator consisting of a VP16 transactivation domain fused to a GAL4 DMA-binding domain and a truncated human progesterone receptor ligand binding domain) in a liver-specific fashion. Significant dose-dependent induction of human growth hormone secretion was noted when mice received the progesterone antagonist RU486 orally or through intraperitoneal injection. The use of chromosomal insulator sequences to minimize position effects on GLVP transactivator expression is also described.
29. 914VPc′) carries a 19 amino acid deletion in the human progesterone receptor ligand-binding domain rather than the 42 amino acid deletion in GLVP and has a carboxyterminally located VP16 transctivation domain. Inducible repression of gene expression is also demonstrated by replacing VP16 with a transcriptional repression domain.
30. Brogden RN, Goa KL, Faulds D: Mifepristone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1993, 45:384-409.
31. Wu S, Gao J, Wu Y, Wu M, Fan H, Yao G, Zheng S, Wang P, Du M, Huang Z et al.: Clinical trial on termination of early pregnancy with RU486 in combination with prostaglandin. Contraception 1992, 46:203-210.
32. Fruman DA, Burakoff SJ, Bierer BE: Immunophilins in protein folding and immunosuppression. FASEB J 1994, 8:391-400.
33. Stoddard BL, Flick KE: Calcineurin-immunosuppressor complexes. Curr Opin Struct Biol 1996, 6:770-775.
34. Ho S, Clipstone N, Timmerman L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR: The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996, 80(suppl):40-45.
35. Belshaw PJ, Ho SN, Crabtree GR, Schreiber SL: Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci USA 1996, 93:4604-4607.
36. Ho SN, Biggar SR, Spencer DM, Schreiber SL, Crabtree GR: Dimeric ligands define a role for transcriptional activation domains in reinitiation. Nature 1996, 382:822-826.
37. Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR: Controlling signal transduction with synthetic ligands. Science 1993, 262:1019-1024.
38. Belshaw PJ, Schoepfer K-Q, Morrison KL, Schreiber SL: Rational design of orthagonal receptor-ligand combinations. Angew Chem Int Ed Engl 1995, 34:2129-2132.
39. Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T, Magari SR, Phillips T, Courage NL, Cerasoli F Jr et al.: A humanized system for pharmacologic control of gene expression. Nat Med 1996, 2:1028-1032.
40. Pomerantz JL, Sharp PA, Pabo CO: Structure-based design of transcription factors. Science 1995, 267:93-96.
41. Magari SR, Rivera VM, Luliucci JD, Gilman M, Cerasoli F Jr: Pharmacologic control of a humanized gene therapy system implanted into nude mice. J Clin Invest 1997, 100:2865-2872. The rapamycin-inducible system described in [36] is used to demonstrate regulated human growth hormone secretion in a cell implantation model in nude mice. These experiments demonstrate that a number of parameters, such as the activity and pharmacokinetics of rapamycin, as well as responsiveness of the cells to inducing compound and number of cells implanted, influence levels of gene expression upon rapamycin stimulation.
42. Liberles SD, Diver ST, Austin DJ, Schreiber SL: Inducible gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen. Proc Natl Acad Sci USA 1997, 94:7825-7830. Synthesis of nonimmunosuppressive rapamycin derivatives with greatly decreased binding affinity for the cellular protein FKBP12-rapamycin-associated protein (FRAP) is described. A mammalian three-hybrid screen was performed to identify compensatory mutations in the rapamycin-binding domain of FRAP to restore binding to these modified derivatives. Inclusion of these components into dimerization-based strategies of gene regulation may increase specificity and decrease toxicity currently associated with the system.
43. Luengo JL, Yamashita DS, Dunnington D, Beck AK, Rozamus LW, Yen H-K, Bossard MJ, Levy MA, Hand A, Newman-Tarr T et al.: Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface. Chem Biol 1995, 2:471-481.
44. Chung JH, Whiteley M, Felsenfeld G: A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 1993, 74:505-514.
45. Festenstein R, Tolaini M, Corbella P, Mamalaki C, Parrington J, Fox M, Miliou A, Jones M, Kioussis D: Locus control region function and heterochromatin-induced position effect variegation. Science 1996, 271:1123-1125.
46. Maxwell IH, Harrison GS, Wood WM, Maxwell FA: A DNA cassette containing a trimerized SV40 polyadenylation signal which efficiently blocks spurious plasmid-initiated transcription in transfected mammalian cells. Biotechniques 1989, 7:276-280.
47. Maxwell IH, Spitzer AL, Long CJ, Maxwell F: Autonomous parvovirus transduction of a gene under control of tissue-specific or inducible promoters. Gene Ther 1996, 3:28-36.